@article{81547413b42246d288ea63558b80f735,
title = "Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement",
author = "Mattia Novo and Ruff, {Michael W.} and Skrabek, {Pamela J.} and Yi Lin",
note = "Funding Information: Potential Competing Interests: Dr Lin serves as a consultant to Kite/Gilead, Novartis, Celgene, JUNO, BlueBird Bio, Janssen, Legend, and Allogene and has received grants from Janssen. Dr Lin has received research funding as a principal investigator of clinical trials from Kite/Gilead, Celgene, BlueBird Bio, Janssen, and Sorrento and served on ad hoc advisory boards of Kite/Gilead, but did not receive personal compensations (all outside the submitted work). The other authors report no competing interests.",
year = "2019",
month = nov,
doi = "10.1016/j.mayocp.2019.09.006",
language = "English (US)",
volume = "94",
pages = "2361--2364",
journal = "Mayo Clinic proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "11",
}